ABSTRACT
"Mimickers" of vasculitis are well-documented in the literature. We report a case of intravenous drug abuse manifesting with signs and symptoms suggestive of vasculitis. This case highlights the need for diagnostic precision in the evaluation of suspected vasculitis.
Subject(s)
Substance Abuse, Intravenous/diagnosis , Vasculitis/diagnosis , Adult , Asthma/complications , Asthma/therapy , Diagnosis, Differential , Female , Foreign Bodies/etiology , Foreign Bodies/pathology , Humans , Lung Diseases, Interstitial/etiology , Lung Diseases, Interstitial/pathologyABSTRACT
GCA presents in various forms, creating a diagnostic conundrum for the treating physician. Evaluation requires extensive medical examination, testing, and imaging to rule out other conditions. Compared with the process of diagnosing GCA, treating it is relatively straightforward. Most patients show significant improvement with corticosteroid therapy. Our patient presented with syncope, which also has numerous causes. Detailed testing confirmed a positional trigger for her syncope in the absence of hemodynamic disturbances. She responded promptly to corticosteroid therapy. We speculate that flow-limiting stenosis in the vertebrobasilar system may have caused her symptoms.
Subject(s)
Confusion/etiology , Giant Cell Arteritis/complications , Giant Cell Arteritis/diagnosis , Headache/etiology , Syncope/etiology , Aged , Anti-Inflammatory Agents/therapeutic use , Biopsy , Diagnosis, Differential , Female , Giant Cell Arteritis/drug therapy , Humans , Prednisone/therapeutic useABSTRACT
OBJECTIVE: To prospectively assess the efficacy of intramuscular (i.m.) triamcinolone acetonide in the treatment of pseudogout. METHODS: Fourteen patients with crystal proven pseudogout presenting with an acute attack within 5 days of onset were treated with intramuscular triamcinolone acetonide 60 mg and followed for 30 days. Patients with inadequate response were eligible for a 2nd triamcinolone acetonide injection on Day 1-2. RESULTS: Twelve patients had contraindication to nonsteroidal antiinflammatory agents (NSAID). Acute arthritis was monoarticular in 10 patients, and involved 2 or more joints in 4 patients. All patients had good clinical response to triamcinolone acetonide based on restoration of near baseline joint range of motion and joint circumference, and at least 50% improvement in patient and physician global assessment. Major clinical improvement occurred by Day 1-2 (2 patients), Day 3-4 (11 patients), and Day 10-14 (one patient). Six patients required a 2nd triamcinolone acetonide injection on Day 1-2. Toxicities were not observed. CONCLUSION: I.m. triamcinolone acetonide appears to be safe, well tolerated, and effective in the treatment of pseudogout. It may be a reasonable alternative therapy when NSAID are contraindicated, and for polyarticular attacks where intraarticular corticosteroids are impractical.
